The BLA acceptance with Priority Review for z-rostudirsen is the primary catalyst, setting up a binary PDUFA event in January 2027. The $431M offering provides ample cash through 2028 but dilutes existing holders by ~13%. Watch for topline ACHIEVE data in Q1 2027 for DM1, which could further de-risk the pipeline. The stock may trade on regulatory milestones rather than quarterly financials.
Price Chart
Executive Summary
Dyne Therapeutics reported Q2 2026 net loss of $1.08 per share, slightly narrower than the $0.97 loss in Q2 2025 but above the consensus estimate of -$0.75. The key catalyst is the FDA acceptance of the BLA for z-rostudirsen in DMD with Priority Review and a PDUFA date of January 21, 2027, alongside completion of enrollment in the ACHIEVE trial for DM1. The company also completed a $431M public offering and expanded its debt facility to $400M, extending cash runway into Q2 2028.
Key Financial Metrics
Key Facts
- BLA for z-rostudirsen (exon 51 DMD) accepted with Priority Review; PDUFA date January 21, 2027
- Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for DM1; topline data Q1 2027
- IND cleared for DYNE-302 in FSHD; Phase 1 trial planned
- Completed $431M public offering (21M shares at $20.50) in July 2026
- Expanded Hercules debt facility to $400M
- Cash position $898.5M at June 30, 2026; cash runway into Q2 2028
- Net loss $178.6M ($1.08/share) vs $110.9M ($0.97/share) in Q2 2025
Financial Impact
EPS beat consensus by $0.02 (2.6%), but net loss widened 61% YoY to $178.6M due to increased R&D and G&A spend ahead of potential commercial launch
Risk Factors
- PDUFA delay or Complete Response Letter for z-rostudirsen
- Dilution from $431M offering (21M new shares)
- ACHIEVE topline data miss in Q1 2027
- R&D spend continues to rise without near-term revenue
- Competition from other DMD exon-skipping therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access